IBA Business Update – First Quarter 2021
Louvain-La-Neuve, Belgium, 20 May 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first quarter ending 31 March 2021.
Group Overview
▪ Strong balance sheet maintained, with EUR 152 million unaudited gross cash (31 Dec 2020: EUR 151.3 million) and EUR 72.6 million unaudited net cash (31 Dec 2020: EUR 65.2 million)
▪ Business operations have remained solid into the first quarter of 2021, albeit with some continuing impact from COVID-19 related installation delays in Proton Therapy alongside some Other Accelerator delays
▪ Continued focus on sustainable growth and profitability, delivering the very best offering and services to our customers, whilst remaining committed to corporate responsibility
▪ As part of a long-term employee incentive plan, IBA’s share buyback program was launched in January 2021 and is almost complete
Olivier Legrain, Chief Executive Officer of IBA commented: “I have been pleased to see IBA’s continued resilience in the first quarter of 2021, with growing momentum in Proton Therapy in the US, continued success in Asia and strong performance in our Dosimetry and Other Accelerators businesses.”
“Our roadmap to sustainable growth and profitability is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. This focus will be reinforced by our continuing commitment to our customers, our employees and to the planet and I am proud of the groundwork we are laying as a company towards a true stakeholder approach to our business.”